Posts Tagged: nanoparticles

Triphase announces positive preclinical results for CBZed-Nano™

Results for results in docetaxel-resistant prostate cancer models presented at the American Association for Cancer Research (AACR) Conference TORONTO and SAN DIEGO (April 18, 2016) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, and the Ontario Institute for Cancer Research (OICR), today announced positive results from a preclinical study of their CBZed-Nano™ (cabazitaxel cellulose nanoparticle) product in docetaxel-resistant prostate cancer mouse models. Preliminary results also showed that the nanoparticles accumulate in intracranial brain ... Read more

U of T researchers demonstrate new class of solar-sensitive nanoparticle

New research emerging from the University of Toronto's Edward S Rogers Sr. Department of Electrical and Computer Engineering is developing and demonstrating a new class of solar-sensitive nanoparticle. MaRS Innovation is working with Professor Ted Sargent, his research team and U of T's Innovations and Partnerships Office (IPO) to incubate and commercialize this and other solar technologies. Their work was recently published in Nature Materials. The paper's publication was widely covered in the technical trades, including CNET.com, Tech Times, Compound Semiconductor.net and ... Read more

Cellax profiled in SciBX; MaRS Innovation’s MSc PoP program cited in National Post supplement

The Cellax technology was profiled in a recent issue of  SciBX (subscription necessary). MaRS Innovation is mentioned in the article as the technology's commercialization agent. Here's an excerpt: "Ontario Institute for Cancer Research scientists have developed glycopolymer-conjugated docetaxel nanoparticles that outperform Abraxane in mouse models of breast cancer. The Ontario Institute for Cancer Research (OICR) is backing the program with $1.5 million to take it to the clinic. The expectation is that the product’s ability to target the tumor stroma rather than the ... Read more

DLVR: Using personalized medicine and nature’s cellular toolkit to target cancer tumours

Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. This post coincided with World Cancer Day. What if you could use a cancer tumour’s proteomic profile to make it easier to target and destroy? Targeting specific proteins on the surface of individual tumours—or, more precisely, targeting a cell receptor that naturally allows substances to pass into a cell—would allow clinicians to more effectively deliver ... Read more

OICR and MaRS Innovation announce funding to develop Cellax™, a nanotechnology-based cancer drug

TORONTO, ON (November 13, 2012) — The Ontario Institute for Cancer Research (OICR) and MaRS Innovation (MI) today announced $1.5 million in funding from OICR over three years to further develop Cellax™, a nanoparticle drug that could offer an alternative to chemotherapy with fewer side effects. “Cellax is promising because it provides a more targeted strategy for treating tumours, killing tumour cells while minimizing the effect on healthy tissue,” said Dr. Rima Al-awar, director, OICR’s Medicinal Chemistry Platform. “OICR is proud to ... Read more

Xagenic secures $1 million investment from Ministry of Research & Innovation

Provincial Investment Supports Commercialization of Leading-Edge Molecular Diagnostic Screening Technology TORONTO (July 26, 2011) — Xagenic Inc., one of MaRS Innovation’s (MI) portfolio spin-off companies, was awarded $1 million in funding by Ontario’s Ministry of Research and Innovation (MRI) through its Investment Accelerator Fund‐Life Sciences (IAF-­LS) program. Research and Innovation Minister Glen Murray made the announcement at MaRS Discovery District. “Today’s announcement will go a long way in helping us to commercialize a technology that will ultimately shape the future of diagnostic testing — instead ... Read more

Xagenic secures $1 million investment in chip-based technology for detecting disease, cancer and infection

Funds secured from MaRS Innovation, HTX, OICR and CCR to speed commercialization of Xagenic's rapid molecular diagnostic technology TORONTO (October 13, 2010) – MaRS Innovation today announced a $500,000 investment in its Toronto-based spin-off company, Xagenic Inc. When combined with funds from other investors and lenders, the new working capital provided to Xagenic totals $1.04 million. This follow‐on financing includes a $300,000 loan from HTX, The Health Technology Exchange; $200,000 from the Ontario Institute for Cancer Research; $40,000 from the Ontario Centre of Excellence ... Read more

Physicist pairs with pharmaceutical scientist to design nano-particles for cancer imaging

TORONTO (November 19, 2009) – In the drive to improve early detection and treatment of cancer, a pair of Toronto scientists has developed a unique technology that combines contrast agents with targeted, long-lasting nano-particles for use in multiple medical imaging platforms. While contrast agents are routinely injected into patients to enhance the quality of medical images, different agents are currently required for various imaging modes (e.g. MRI, CT, PET) each with inherent strengths and limitations. By combining more than one contrast agent into a nano-particle ... Read more